Anticoagulation for Acute Proximal DVT in Severe Renal Impairment (CrCl < 30 mL/min)
Severe renal impairment requires selection of agents with minimal renal clearance and dose adjustment to avoid accumulation. Current guidelines endorse unfractionated heparin (UFH) or low‑molecular‑weight heparin (LMWH) with renal‑adjusted dosing for these patients [1].
Preferred Agents
- Unfractionated heparin (UFH)
-
Intravenous continuous infusion preferred when rapid reversibility is needed.
-
Low‑molecular‑weight heparin (LMWH)
- Acceptable alternative if dose is reduced for CrCl < 30 mL/min.
UFH Dosing and Monitoring
- Initial bolus: 80 U/kg (maximum 5,000 U) [1].
- Maintenance infusion: 18 U/kg/h, titrated to achieve activated partial thromboplastin time (aPTT) 1.5–2.5 × control [1].
- Adjust infusion rate based on aPTT values every 4–6 hours until therapeutic range is reached.
LMWH Dosing Adjustments
- Enoxaparin: 1 mg/kg subcutaneously once daily (instead of twice daily) [1].
- Dalteparin: 200 U/kg subcutaneously once daily [1].
- Tinzaparin: 175 U/kg subcutaneously once daily [1].
- Monitor anti‑factor Xa levels 4 hours post‑dose; target peak 0.5–1.0 IU/mL for therapeutic dosing [1].
Transition to Oral Anticoagulation
- After 5–7 days of parenteral therapy and once renal function remains stable, transition to a direct oral anticoagulant (DOAC) is generally not recommended for CrCl < 30 mL/min; warfarin remains the oral option [1].
Contraindications and Precautions
- Avoid full therapeutic LMWH dosing without adjustment in severe renal impairment due to bleeding risk [1].
- Use UFH when immediate reversal may be required (e.g., peri‑operative period, bleeding).
Summary of Recommendations
- Offer UFH or renal‑adjusted LMWH to all hospitalized patients with acute proximal DVT and CrCl < 30 mL/min [1].
- Prefer UFH for patients at high bleeding risk or requiring rapid reversal.
- Apply documented dose reductions for LMWH agents and monitor anti‑Xa levels where available [1].